Abstract
Objective of the Paper: To evaluate the dynamics of the course of HER2/neu–positive breast cancer with heterogeneity of HER2/neu amplification in the luminal subtype. Key points. A clinical case of heterogeneity of HER2/neu amplification in luminal in HER2/neu–positive breast cancer in a patient who received treatment at the Medical Center “Medical City” (Tyumen). Secondary edematous–infiltrative form, metastases to the axillary lymph nodes on the right сT4bN2a, stage IIIb. Conclusion. Currently, the status of HER2/neu can be influenced by a combination of neoadjuvant polychemotherapy and HER2–targeted therapy, which determines the frequency of relapses, the outcome of the disease, which necessitates the need to perform a regular check procedure. Keywords: neoadjuvant chemotherapy, breast cancer, clinical case, HER2, transformation.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
